These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 17196564

  • 21. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.
    Morelli M, Pinna A.
    Neurol Sci; 2001 Feb; 22(1):71-2. PubMed ID: 11487207
    [Abstract] [Full Text] [Related]

  • 22. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
    Carta AR, Pinna A, Tronci E, Morelli M.
    Neurology; 2003 Dec 09; 61(11 Suppl 6):S39-43. PubMed ID: 14663008
    [Abstract] [Full Text] [Related]

  • 23. New adenosine A2A receptor antagonists: actions on Parkinson's disease models.
    Pinna A, Volpini R, Cristalli G, Morelli M.
    Eur J Pharmacol; 2005 Apr 11; 512(2-3):157-64. PubMed ID: 15840400
    [Abstract] [Full Text] [Related]

  • 24. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
    Pinna A, Bonaventura J, Farré D, Sánchez M, Simola N, Mallol J, Lluís C, Costa G, Baqi Y, Müller CE, Cortés A, McCormick P, Canela EI, Martínez-Pinilla E, Lanciego JL, Casadó V, Armentero MT, Franco R.
    Exp Neurol; 2014 Mar 11; 253():180-91. PubMed ID: 24412491
    [Abstract] [Full Text] [Related]

  • 25. Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535.
    Galluzzo M, Pintor A, Pèzzola A, Grieco R, Borsini F, Popoli P.
    Eur J Pharmacol; 2008 Jan 28; 579(1-3):149-52. PubMed ID: 18036583
    [Abstract] [Full Text] [Related]

  • 26. Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
    Mandel RJ.
    Exp Neurol; 2000 Jan 28; 161(1):212-9. PubMed ID: 10683287
    [Abstract] [Full Text] [Related]

  • 27. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M, Usiello A, Carta M, Håkansson K, Fisone G, Cenci MA.
    Exp Neurol; 2005 Jul 28; 194(1):66-75. PubMed ID: 15899244
    [Abstract] [Full Text] [Related]

  • 28. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
    Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA.
    J Neurochem; 2006 Mar 28; 96(6):1718-27. PubMed ID: 16539687
    [Abstract] [Full Text] [Related]

  • 29. Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
    Glavan G, Zivin M.
    Neuroscience; 2005 Mar 28; 135(2):545-54. PubMed ID: 16111820
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice.
    Yu L, Schwarzschild MA, Chen JF.
    Neurosci Lett; 2006 Jan 23; 393(1):31-5. PubMed ID: 16236444
    [Abstract] [Full Text] [Related]

  • 32. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P.
    Mov Disord; 2004 Jan 23; 19(1):15-21. PubMed ID: 14743355
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
    Chao OY, Mattern C, Silva AM, Wessler J, Ruocco LA, Nikolaus S, Huston JP, Pum ME.
    Brain Res Bull; 2012 Feb 10; 87(2-3):340-5. PubMed ID: 22108632
    [Abstract] [Full Text] [Related]

  • 37. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.
    Tanganelli S, Sandager Nielsen K, Ferraro L, Antonelli T, Kehr J, Franco R, Ferré S, Agnati LF, Fuxe K, Scheel-Krüger J.
    Parkinsonism Relat Disord; 2004 Jul 10; 10(5):273-80. PubMed ID: 15196505
    [Abstract] [Full Text] [Related]

  • 38. Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.
    Frau L, Borsini F, Wardas J, Khairnar AS, Schintu N, Morelli M.
    Synapse; 2011 Mar 10; 65(3):181-8. PubMed ID: 20665698
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL, Gupta V, Alam S, Park JY, Bishop C.
    Pharmacol Biochem Behav; 2007 Mar 10; 87(3):306-14. PubMed ID: 17553556
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.